Interleukin 17 receptor type A (IL17RA) is a potent mediator in the pathogenesis and progression of colorectal cancer. Our previous study has shown that IL17A is a potential therapeutic target in modulating tumorigenesis, and metastasis, and serves as a prognostic marker in colorectal cancer (CRC), but the role of IL17RA in colonic tumorigenesis is still not clear. This study aims to evaluate the potential role and function of IL17RA in CRC.
IL17RA expression was determined in colorectal cancer tissues and adjacent normal tissues of CRC patients by using quantitative RT-PCR and immunohistochemistry. To investigate the functional significance of IL17RA expression, and clinical significance of IL17RA expression in CRC patients, disease-free survival was analyzed in patients with CRC. The IL17RA knockdown stable clones were used for in vitro migration/invasion assay and were subcutaneously implanted in mice to measure tumor growth.
A higher IL17RA mRNA level in tumor tissue of CRC patients than adjacent normal tissues (p = 0.0016) was found and it was significantly correlated with recurrence (p = 0.008) and poor disease-free survival (P
IL-17RA participates in mediating tumor growth and angiogenesis of CRC and plays a crucial role in the progression of CRC. It could serve as prognostic marker of CRC patients and could potentially be used as a therapeutic target in clinical application.
Clinical trial identification
Legal entity responsible for the study
All authors have declared no conflicts of interest.